• Je něco špatně v tomto záznamu ?

Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients

AT. Kunzmann, MA. Proença, HW. Jordao, K. Jiraskova, M. Schneiderova, M. Levy, V. Liska, T. Buchler, L. Vodickova, V. Vymetalkova, AE. Silva, P. Vodicka, DJ. Hughes,

. 2019 ; 38 (10) : 1891-1899. [pub] 20190731

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006091

Grantová podpora
HRA-PHS/2015/1142 Health Research Board of Ireland (HRB)
13/ISCA/2843 Science Foundation Ireland - Ireland
AZV 15-27580A; AZV NV 18-03-00199 Ministry of Health of the Czech Republic
NV15-27580A MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek

E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 31367996
DOI 10.1007/s10096-019-03649-1
Knihovny.cz E-zdroje

There is increasing evidence indicating a role for Fusobacterium nucleatum (F. nucleatum) in colorectal cancer (CRC) development and prognosis. This study evaluated F. nucleatum as a prognostic biomarker, by assessing its association with post-diagnosis survival from CRC. From September 2008 to April 2012 CRC patients (n = 190) were recruited from three hospitals within the Czech Republic. F. nucleatum DNA copies were measured in adjacent non-malignant and colorectal tumor tissues using quantitative real-time PCR. Cox Proportional Hazards (HR) models were applied to evaluate the association between F. nucleatum DNA and overall survival, adjusting for key confounders. Risk prediction modeling was conducted to evaluate the ability to predict survival based on F. nucleatum status. High, compared with low, levels of F. nucleatum in colorectal tumor tissues were associated with poorer overall survival (adjusted HR 1.68, 95% CI 1.02-2.77), which was slightly attenuated after additional adjustment for microsatellite instability status. However, inclusion of F. nucleatum in risk prediction models did not improve the ability to identify patients who died beyond known prognostic factors such as disease pathology staging. Although the increased presence of F. nucleatum was associated with poorer prognosis in CRC patients, this may have limited clinical relevance as a prognostic biomarker.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006091
003      
CZ-PrNML
005      
20200522103750.0
007      
ta
008      
200511s2019 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10096-019-03649-1 $2 doi
035    __
$a (PubMed)31367996
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kunzmann, Andrew T $u Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland. A.Kunzmann@qub.ac.uk.
245    10
$a Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients / $c AT. Kunzmann, MA. Proença, HW. Jordao, K. Jiraskova, M. Schneiderova, M. Levy, V. Liska, T. Buchler, L. Vodickova, V. Vymetalkova, AE. Silva, P. Vodicka, DJ. Hughes,
520    9_
$a There is increasing evidence indicating a role for Fusobacterium nucleatum (F. nucleatum) in colorectal cancer (CRC) development and prognosis. This study evaluated F. nucleatum as a prognostic biomarker, by assessing its association with post-diagnosis survival from CRC. From September 2008 to April 2012 CRC patients (n = 190) were recruited from three hospitals within the Czech Republic. F. nucleatum DNA copies were measured in adjacent non-malignant and colorectal tumor tissues using quantitative real-time PCR. Cox Proportional Hazards (HR) models were applied to evaluate the association between F. nucleatum DNA and overall survival, adjusting for key confounders. Risk prediction modeling was conducted to evaluate the ability to predict survival based on F. nucleatum status. High, compared with low, levels of F. nucleatum in colorectal tumor tissues were associated with poorer overall survival (adjusted HR 1.68, 95% CI 1.02-2.77), which was slightly attenuated after additional adjustment for microsatellite instability status. However, inclusion of F. nucleatum in risk prediction models did not improve the ability to identify patients who died beyond known prognostic factors such as disease pathology staging. Although the increased presence of F. nucleatum was associated with poorer prognosis in CRC patients, this may have limited clinical relevance as a prognostic biomarker.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biologické markery $x analýza $7 D015415
650    _2
$a kohortové studie $7 D015331
650    _2
$a kolorektální nádory $x mortalita $x patologie $7 D015179
650    _2
$a DNA bakterií $x analýza $7 D004269
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a infekce bakteriemi rodu Fusobacterium $x mikrobiologie $7 D005674
650    _2
$a Fusobacterium nucleatum $x genetika $7 D016967
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a analýza přežití $7 D016019
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Proença, Marcela Alcântara $u Department of Biology, São Paulo State University, UNESP, São José do Rio Preto, SP, Brazil.
700    1_
$a Jordao, Haydee Wt $u Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland.
700    1_
$a Jiraskova, Katerina $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Schneiderova, Michaela $u Department of Surgery, General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Levy, Miroslav $u Department of Surgery, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
700    1_
$a Liska, Václav $u Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
700    1_
$a Vodickova, Ludmila $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Vymetalkova, Veronika $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Silva, Ana Elizabete $u Department of Biology, São Paulo State University, UNESP, São José do Rio Preto, SP, Brazil.
700    1_
$a Vodicka, Pavel $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Hughes, David J $u Cancer Biology and Therapeutics Group, School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, D04 V1W8, Ireland. david.hughes@ucd.ie.
773    0_
$w MED00001612 $t European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology $x 1435-4373 $g Roč. 38, č. 10 (2019), s. 1891-1899
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31367996 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200522103748 $b ABA008
999    __
$a ok $b bmc $g 1524949 $s 1096147
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 38 $c 10 $d 1891-1899 $e 20190731 $i 1435-4373 $m European journal of clinical microbiology & infectious diseases $n Eur J Clin Microbiol Infect Dis $x MED00001612
GRA    __
$a HRA-PHS/2015/1142 $p Health Research Board of Ireland (HRB)
GRA    __
$a 13/ISCA/2843 $p Science Foundation Ireland $2 Ireland
GRA    __
$a AZV 15-27580A; AZV NV 18-03-00199 $p Ministry of Health of the Czech Republic
GRA    __
$a NV15-27580A $p MZ0
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace